Refractory Mycoplasma pneumoniae with cytokine storm: a case report with an atypical presentation
DOI:
https://doi.org/10.18203/2349-3291.ijcp20253788Keywords:
Refractory mycoplasma, Cytokine storm, M. pneumoniaeAbstract
Mycoplasma pneumoniae is a significant cause of community-acquired pneumonia in children. Macrolide-resistant M. pneumoniae (MRMP) has been observed worldwide, with varying incidence rates. MRMP infections have a poor response to macrolide antibiotics, which further results in prolonged fever, extended antibiotic treatment, increased hospitalization, critical care unit admissions, and a significantly higher proportion of patients needing to receive glucocorticoids or second-line antibiotics. A 5-year-old girl presented with high-grade fever and lobar consolidation due to M. pneumoniae. She didn’t respond to macrolides. She developed features of cytokine storm with elevated ferritin, transaminitis etc. She was started on levofloxacin, given intravenous immunoglobulin and systemic corticosteroids, following which defervescence occurred. Early and rapid identification of resistant Mycoplasma infection is important. Appropriate antibiotic treatment, along with immunosuppressive therapy, is warranted for children with refractory M. pneumoniae pneumonia (MRMP).
Metrics
References
Kim K, Jung S, Kim M, Park S, Yang HJ, Lee E. Global trends in the proportion of macrolide-resistant Mycoplasma pneumoniae infections: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(7):e2220949. DOI: https://doi.org/10.1001/jamanetworkopen.2022.20949
Lanata MM, Wang H, Everhart K, Moore-Clingenpeel M, Ramilo O, Leber A. Macrolide-resistant Mycoplasma pneumoniae infec tions in children, Ohio, USA. Emerg Infect Dis. 2021;27(6):1588-97. DOI: https://doi.org/10.3201/eid2706.203206
Yang HJ. Benefits and risks of therapeutic alternatives for mac rolide resistant Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr. 2019;62:199-205. DOI: https://doi.org/10.3345/kjp.2018.07367
Zhang Y, Zhou Y, Li S, Yang D, Wu X, Chen Z. The clinical characteristics and predictors of refractory Mycoplasma pneumoniae pneumonia in children. PLoS One. 2016;11:e0156465. DOI: https://doi.org/10.1371/journal.pone.0156465
Lee YC, Chang CH, Lee WJ, Liu TY, Tsai CM, Tsai TA, et al. Altered chemokine profile in refractory Mycoplasma pneumoniae pneumonia infected children. J Microbiol Immunol Infect. 2021;54:673-9. DOI: https://doi.org/10.1016/j.jmii.2020.03.030
Zhao F, Li J, Liu J, Guan X, Gong J, Liu L, et al. Antimicro bial susceptibility and molecular characteristics of Mycoplasma pneumoniae isolates across different regions of China. Antimicrob Resist Infect Control. 2019;8:143. DOI: https://doi.org/10.1186/s13756-019-0576-5
Chen YC, Hsu WY, Chang TH. Macrolide-resistant Mycoplasma pneumoniae infections in pediatric community-acquired pneumo nia. Emerg Infect Dis. 2020;26:1382-91 DOI: https://doi.org/10.3201/eid2607.200017
Chou CC, Shen CF, Chen SJ, Chen HM, Wang YC, Chang WS, et al. Recommendations and guidelines for the treatment of pneumonia in Taiwan Province of China. J Microbiol Immunol Infect. 2019;52(1):172-99. DOI: https://doi.org/10.1016/j.jmii.2018.11.004
Kim HS, Sol IS, Li D, Choi M, Choi YJ, Lee KS, et al. Efficacy of glucocorticoids for the treatment of macrolide refractory Mycoplasma pneumoniae in children: meta-analysis of randomized controlled trials. BMC Pulm Med. 2019;19(1):251. DOI: https://doi.org/10.1186/s12890-019-0990-8
Shan LS, Liu X, Kang XY, Wang F, Han XH, Shang YX. Effects of methylprednisolone or immunoglobulin when added to stand and treatment with intravenous azithromycin for refractory Myco plasma pneumoniae pneumonia in children. World J Pediatr. 2017;13(4):321-7. DOI: https://doi.org/10.1007/s12519-017-0014-9
Downloads
Published
How to Cite
Issue
Section
